LQDA · available-data snapshot
Liquidia Corporation (LQDA): Available-Data Snapshot
TickerWorth does not publish a DCF fair value for Liquidia Corporation (LQDA); the reason is set out below. What its filings and market data do show is below. The snapshot also sets out its trading multiples against 5 peers. Snapshot as of Oct 19, 2026.
Model by Miraaj Patel · generated from public market data · Updated Oct 19, 2026 · How these pages are made
Why is there no fair value for LQDA?
We do not publish a fair value for Liquidia Corporation. What we can say from its filings and market data is below.
What is LQDA's TickerWorth Score?
A stronger business than most — priced richly vs peers
Compared with Healthcare companies in US
Its strongest point: a profitable, high-quality business. Its weakest: looks expensive on the numbers.
- Value · 40 of 100
Cheaper than 40% of Healthcare companies in US
- Price vs worth · 54 of 100
- Quality · 97 of 100
More profitable than 97% of Healthcare companies in US
- Financial health · 54 of 100
Financially stronger than 54% of Healthcare companies in US
- Growth · 76 of 100
Growing faster than 76% of Healthcare companies in US
- Momentum · 48 of 100
Outperformed 48% of Healthcare companies in US over the past year
Confidence: Medium confidence · Scored
Get the Undervalued Company of the Week.
- Price
- $34.64
- Market cap
- $3,
100, 587, 776 - 52-week high
- $93.61
- 52-week low
- $21.94
- Currency
- USD
- Exchange
- NasdaqCM
Snapshot of Oct 19, 2026, quote time not published · Prices are delayed.
What we can say
We don't publish a discounted-cash-flow fair value for Liquidia Corporation (LQDA) because the free data sources we rely on don't expose the multi-year financials a DCF needs — common for small or thinly-covered listings. Rather than invent numbers, this page shows an honest snapshot of what the public data does support: the current price and size, any relative valuation multiples that exist, a book-value view, and a price-based read. Treat it as a descriptive starting point, not a valuation and not investment advice.
Read the full reasoning
On the numbers we do have, LQDA trades at a recent price of $34.64, a market capitalisation of about $3,100,587,776, sitting 18% of the way up its 52-week range ($21.94–$93.61), on the NasdaqCM.
The standard alternative to a DCF is relative valuation — comparing LQDA's trading multiples against a sector benchmark. Here that gives P/E of 24.9× (cheaper than the peer median of 42.2×); Fwd P/E of 15.8× (cheaper than the peer median of 17.6×); P/B of 15.8× (richer than the peer median of 7.9×); P/S of 6.9× (richer than the peer median of 6.2×); EV/EBITDA of 17.5× (in line with the peer median of 18.5×). A cheaper multiple than peers can flag a discount or a market that expects weaker growth; it is a comparison, not a recommendation.
The asset, or book-value, lens is the classic tool for asset-heavy businesses and financials. LQDA shows a price-to-book (P/B) of 15.82 and book value of $2.19 per share. Price-to-book compares the market price to the accounting net-asset value per share; below 1.0 can mean a discount to net assets or that the market is pricing in trouble — descriptive either way, never a buy signal on its own.
Finally, a price-based read — explicitly not a valuation. LQDA is in a mixed trend, trading -63.0% from its 52-week high. Over the past year the stock is +40.5%. Moving-average trend and 52-week position describe where the stock has traded; they say nothing about what it is worth.
LQDA vs peers
Sector benchmark (bellwethers, not direct competitors).
| Multiple | LQDA | Peer median | Read |
|---|---|---|---|
| P/E | 24.9× | 42.2× | cheaper than |
| Fwd P/E | 15.8× | 17.6× | cheaper than |
| P/B | 15.8× | 7.9× | richer than |
| P/S | 6.9× | 6.2× | richer than |
| EV/EBITDA | 17.5× | 18.5× | in line with |
What does Liquidia Corporation do?
What does it do?
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It operates in the Drug Manufacturers - Specialty & Generic industry (Healthcare sector), headquartered in United States. The company employs roughly 216 people.
How does it make money?
The business turns $451M in annual revenue into profit. Out of every $100 of sales, about $50 is left as operating profit (operating margin of 49.8%), after a 93% gross margin on the products/services it sells. After all costs, taxes and interest, 30.7% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks solid: carries modest debt (0.9× equity), comfortably covers its short-term bills (2.3× current ratio), and is currently profitable.
Who at LQDA filed insider trades?
| Date | Insider | Relationship | What happened | Value | Filing |
|---|---|---|---|---|---|
| Schundler Russell | General Counsel | Open-market sale | $389,948.16 | Form 4 for Schundler Russell (opens sec.gov in a new tab) | |
| Saggar Rajeev | Chief Medical Officer | Open-market sale | $262,528.64 | Form 4 for Saggar Rajeev (opens sec.gov in a new tab) | |
| Moomaw Scott | Chief Commercial Officer | Open-market sale | $252,418.24 | Form 4 for Moomaw Scott (opens sec.gov in a new tab) | |
| Krepp Sarah | Chief Human Resource Officer | Open-market sale | $149,377.60 | Form 4 for Krepp Sarah (opens sec.gov in a new tab) | |
| Khindri Sanjeev | Chief Development Officer | Open-market sale | $31,356.48 | Form 4 for Khindri Sanjeev (opens sec.gov in a new tab) | |
| Kaseta Michael | CFO and COO | Open-market sale | $539,354.24 | Form 4 for Kaseta Michael (opens sec.gov in a new tab) |
A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans
Companies we do put a number on
Not investment advice. TickerWorth Score is a model output.
A descriptive, available-data snapshot and relative comparison — NOT a DCF, NOT a price target, and NOT investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public market data that can be wrong, stale or incomplete.